Supplemental Digital Content is available in the text.

No abstract

Background/Objectives: Helicobacter pylori (H. pylori) is the most common chronic bacterial infection. Patients with H. pylori infection may be at an increased risk of nonalcoholic fatty liver disease (NAFLD) because of chronic inflammation and insulin resistance. Several epidemiologic studies attempting to determine this risk have yielded inconsistent results. This meta-analysis was conducted with the aims to summarize all available evidence and estimate the risk of NAFLD in patients with H. pylori infection. Methods: A literature search was performed using MEDLINE and EMBASE database from inception to June 2016. Studies that reported relative risks, odd ratios, or hazard ratios comparing the risk of NAFLD among patients with H. pylori infection versus without H. pylori infection were included. Pooled odds ratios and 95% confidence intervals were calculated using a random-effect, generic inverse variance method. Results: Six studies met our eligibility criteria and were included in this analysis. We found a statistically significant increased risk of NAFLD among patients with H. pylori infection with the pooled odds ratios of 1.21 (95% confidence interval, 1.07-1.37). The statistical heterogeneity was low with an I 2 of 49%. Conclusions: A significantly increased risk of NAFLD among patients with H. pylori infection was demonstrated in this meta-analysis. Further studies are required to clarify how this risk should be addressed in clinical practice.

Background/Aim:The association between sarcopenia and nonalcoholic fatty liver disease (NAFLD) has been suggested by recent epidemiological studies, although the results have been inconsistent. This meta-analysis was conducted to summarize all available data and estimate the risk of NAFLD among patients with sarcopenia.Materials and Methods:A comprehensive literature review was conducted using MEDLINE and EMBASE databases through November 2016 to identify all studies that compared the risk of NAFLD among patients with sarcopenia versus those without sarcopenia. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird.Results:Five cross-sectional studies with 27,804 participants met the eligibility criteria and were included in the meta-analysis. The risk of NAFLD in patients with sarcopenia was significantly higher than those without sarcopenia with the pooled odds ratio of 1.54 (95% confidence interval, 1.05–2.26). The statistical heterogeneity was high with an I2of 83%.Conclusions:A significantly increased risk of NAFLD among patients with sarcopenia was observed in this study.

Our study demonstrates no significant association between coffee consumption and CKD in males. However, future studies are required to assess a potential inverse association between coffee consumption and risk for developing CKD in females.